Efficacy of Biosimilar Adalimumab in the Treatment of Behcet's Uveitis

Purpose: This study aimed to evaluate biosimilar adalimumab's efficacy and safety in patients with Behcet's uveitis in Iran. Methods: We performed a study on patients who mostly (79.2%) had a failure on conventional treatment with the mean follow-up time of 19.24 months (95% confidence interval (CI), 16.52-21.96). All the enrolled patients were anti-tumor necrosis factor (anti-TNF) naiive. The primary endpoint was best-corrected visual acuity (BCVA) improvement, and the secondary endpoints were changes in macular thickness, vitreous haze grade, anterior chamber (AC) cell grade, prednisolone dose, and the incidence of adverse reactions. Results: Forty-eight patients were enrolled in the study. After adalimumab use, visual acuity improved significantly (p-value<.001); vitreous haze grade decreased (p-value<.001), and AC cell grade improved (p-value = .002). Macular thickness decreased, but its change was not statistically significant (p-value = .1). Moreover, adalimumab showed a corticosteroid-sparing effect (p-value = .03). Conclusion: Biosimilar adalimumab (CinnoRA (R)) is effective and well-tolerated in Behcet's uveitis.

Automated summary

The study demonstrated that biosimilar adalimumab (CinnoRA (R)) is effective and well-tolerated in patients with Behcet's uveitis, improving visual acuity, reducing vitreous haze, and improving anterior chamber cell grade, with a corticosteroid-sparing effect.